StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences total assets

Total assets on the balance sheet at the end of each period.

Inhibrx Biosciences's total assets was $220.29M at Sep 30, 2026. For fiscal 2025 it was $146.48M, down 19.0% from the year before. The highest annual figure on record is $307.89M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$146.48M-19.0%
FY2024Dec 31, 2024$180.77M-41.3%
FY2023Dec 31, 2023$307.89M+5.9%
FY2022Dec 31, 2022$290.88M+93.3%
FY2021Dec 31, 2021$150.45M+4.7%
FY2020Dec 31, 2020$143.74M+442.6%
FY2019Dec 31, 2019$26.49M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$220.29M+24.1%
Q2 FY2026Jun 30, 2026$154.22M-27.3%
Q1 FY2026Mar 31, 2026$183.97M-24.2%
Q4 FY2025Dec 31, 2025$146.48M-19.0%
Q3 FY2025Sep 30, 2025$177.47M-20.3%
Q2 FY2025Jun 30, 2025$212.12M-17.9%
Q1 FY2025Mar 31, 2025$242.64M-15.9%
Q4 FY2024Dec 31, 2024$180.77M-41.3%
Q3 FY2024Sep 30, 2024$222.56M-40.3%
Q2 FY2024Jun 30, 2024$258.42M+21.2%
Q1 FY2024Mar 31, 2024$288.58M+13.7%
Q4 FY2023Dec 31, 2023$307.89M+5.9%
Q3 FY2023Sep 30, 2023$372.73M+126.1%
Q2 FY2023Jun 30, 2023$213.17M+10.3%
Q1 FY2023Mar 31, 2023$253.72M+57.4%
Q4 FY2022Dec 31, 2022$290.88M+93.3%
Q3 FY2022Sep 30, 2022$164.85M+27.6%
Q2 FY2022Jun 30, 2022$193.21M+36.2%
Q1 FY2022Mar 31, 2022$161.18M+29.5%
Q4 FY2021Dec 31, 2021$150.45M+4.7%
Q3 FY2021Sep 30, 2021$129.18M-10.0%
Q2 FY2021Jun 30, 2021$141.89M+435.6%
Q1 FY2021Mar 31, 2021$124.50M–
Q4 FY2020Dec 31, 2020$143.74M–
Q3 FY2020Sep 30, 2020$143.55M–
Q4 FY2019Dec 31, 2019$26.49M–

More Inhibrx Biosciences figures

See a number that looks wrong?